Second, a large clinical study suggested that endocan levels can function as a prognostic marker in patients with hematological malignancies and life-threatening complications following therapy [32]; further studies must clarify whether endocan can be used as an early marker for severe complications following intensive antileukemic treatment. The gene discussed is ESM1; the disease is hematologic disorder.